You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Advanced Assessment to Accelerate Diagnostic Skill Acquisition
SBC: Parallel Consulting, LLC Topic: NIGMSDESCRIPTION (provided by applicant): Current approaches to medical education produce new physicians with insufficient clinical competency to practice effectively with limited supervision, which has serious implications for patient outcomes during hospitaloff hours. Up to 70% of patients admitted to a hospital are admitted on nights or weekends, when staffing is low and residents may be in charge o ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget
SBC: DOTY SCIENTIFIC, INC. Topic: NIA? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A molecularly targeted pre- and post-exposure vaccine for anthrax
SBC: VLP BIOTECH, INC. Topic: NIAIDDESCRIPTION provided by applicant We have shown that immunization of rabbits with multiple antigenic peptides MAPs displaying sequence from domain of protective antigen PA elicit antibodies specific for a linear determinant within the loop of PA that mediate potent neutralization of lethal toxin LeTx in vitro We have now shown in two separate large studies that antibodies aga ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Amplification-free megabase target-enrichment for next-generation sequencing
SBC: MISSION BIO INC Topic: NHGRIDESCRIPTION (provided by applicant): Target enrichment for next-generation sequencing enables researchers to reduce the burden of sequence data analysis, obtain higher levels of statistical significance by examining more genomes and increase sequencing coverage depth. The goal of this STTR proposal is to develop and commercialize a novel technology capable of amplification-free megabase target seq ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A novel diagnostic test for Irinotecan and Topotecan sensitivity
SBC: RG Biopharma Topic: NCIDESCRIPTION (provided by applicant): The long term objective of this Phase 1 study is to produce an antibody-based diagnostic assay to detect tumor responsiveness to a widely used class of chemotherapeutic agents derived from camptothecin that includes Irinotecan and Topotecan. The assay will be based on a novel biomarker associated with cellular sensitivity to camptothecin and will have clinical ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
A novel vaccine against vaginal Chlamydia trachomatis
SBC: EPITOGENESIS INC Topic: NIAIDDESCRIPTION (provided by applicant): Preventing Chlamydia trachomatis (Ct) infections represent a critical unmet medical need. Development of an effective vaccine would not only reduce the morbidity associated with these infections, including pelvic inflammatory disease (PID), infertility, chronic pelvic pain and ectopic pregnancy, but could also reduce collateral riss including HIV transmission. ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery
SBC: SORRENTO THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION provided by applicant Antibody therapy for serious bacterial infections using polyclonal immune antitoxin or anti capsule horse serum actually predates small molecule antibiotic use However for reasons of safety convenient empirical use and cost the development of broader spectrum antibiotics rapidly supplanted the use of immune serum But drug resistance is quickly reducing th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
ASC101 Enhancement of Regenerative Capacity of Amniotic Fluid-derived Stem Cells
SBC: TARGAZYME, INC. Topic: NHLBIDESCRIPTION (provided by applicant): In the present STTR we propose to investigate two novel approaches in our exploration of the therapeutic and regenerative potential of cell-based medicine. Furthermore, we will utilize a preclinical animal model of compression syndrome (CS) that mimics the pathophysiology of multiple injuries such as crush injuries, burns, circulation blockage, fractures, hemor ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
A simple assay system for rapid detection of circulating tumor cells
SBC: TELOVISION, LLC Topic: NCIDESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors
SBC: ARISAPH PHARMACEUTICALS, INC. Topic: NCIDESCRIPTION (provided by applicant): In the United States colorectal cancer (CRC) is the third leading cause of cancer mortality. Surgery is the primary treatment for early stage CRC; but adjuvant therapy is usually needed in advanced disease. Approximately 55% of CRC patients have metastatic disease for which the prognosis is poor despite incremental improvements due to introduction of irinotecan ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health